KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1532-2807
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
KRAS Status is Associated with Metabolic Parameters in Metastatic Colorectal Cancer According to Primary Tumour Location ; day:27 ; month:6 ; year:2020 ; pages:1-12
Pathology & oncology research ; (27.6.2020), 1-12
- Creator
-
Tabuso, M.
Christian, M.
Kimani, P. K.
Gopalakrishnan, K.
Arasaradnam, R. P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12253-020-00850-y
- URN
-
urn:nbn:de:101:1-2020082321325909385519
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:49 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Tabuso, M.
- Christian, M.
- Kimani, P. K.
- Gopalakrishnan, K.
- Arasaradnam, R. P.
- SpringerLink (Online service)
Other Objects (12)
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network
Kras
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network
Kras
Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
Advances in KRAS mutation inhibition in metastatic colorectal cancer
Prognostic Implication of Urothelial Stem Cell Markers Differs According to Primary Tumour Location in Non-Muscle-Invasive Bladder Cancer
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients
Impact of Primary Tumour Location and Early Tumour Shrinkage on Outcomes in Patients with RAS Wild-Type Metastatic Colorectal Cancer Following First-Line FOLFIRI Plus Panitumumab
Bony tumour in an unusual location on the mandible
Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
Long-Term Survival with Regorafenib in KRAS-Mutated Metastatic Rectal Cancer
KRAS and BRAF mutations in circulating tumour DNA from locally advanced rectal cancer
The impact of KRAS mutations on VEGF-A production and tumour vascular network